The effects of selected biologics and a small molecule on Health-Related Quality of Life in adult plaque psoriasis patients: A systematic review and meta-analysis.

Anna Karpińska-MireckaJoanna BartosińskaDorota Maria Krasowska

Published in: PloS one (2020)

Infliximab, adalimumab, ixekizumab, secukinumab and tofacitinib in adult plaque psoriatic patients improved HRQOL measured by the DLQI. The patients with lower quality of life before treatment obtained better results.

Keyphrases

end stage renal disease
small molecule
rheumatoid arthritis
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
coronary artery disease
ulcerative colitis
systemic lupus erythematosus
disease activity
juvenile idiopathic arthritis
childhood cancer
smoking cessation